Sharenet Sites 
Sharenet Sites
Unaudited interim financial results for the six months ended 31 December 2017
ASPEN PHARMACARE HOLDINGS LIMITED AND ITS SUBSIDIARIES ("Aspen" or "the Group")
(Registration number 1985/002935/06)
Share code: APN
ISIN: ZAE000066692
Unaudited interim financial results for the six months ended 31 December 2017
COMMENTARY
GROUP PERFORMANCE
Revenue generated by the Group grew 11% to R21,9 billion, normalised EBITDA1 improved 15% to R6,3 billion
and normalised headline earnings per share ("NHEPS") increased by 26% to 872 cents for the six months ended
31 December 2017.
The significant influences on performance were:
- Healthy organic growth driven by continued positive momentum in performance from the South African
pharmaceutical business and a strong result from the Thrombosis Brands;
- The inclusion for the full period of the AstraZeneca ("AZ") global (excluding the USA) anaesthetic portfolio
("AZ Anaesthetics") for which the commercial rights were acquired with effect from 1 September 2016. The
profitability of the AZ Anaesthetics was further enhanced by the acquisition, with effect from 1 October 2017,
of the residual rights to the portfolio for a consideration of USD555 million plus further performance-related
payments of up to USD211 million;
- Improved profit margins were further assisted by the effect of synergies and higher volumes lowering unit
cost of goods;
- Additional operating expenditure related to the development of structures in China and Japan; and
- The reversal of foreign exchange losses incurred in the prior period.
Relative exchange rate movements had a marginally favourable impact on financial performance as is
illustrated in the table below which compares performance for the reporting period to performance in the prior
comparable period at previously reported exchange rates and then at constant exchange rates ("CER").
Change at Change
Reported Reported reported CER* 2017/2016
2017 2016 rates 2016 at CER
Six months ended 31 December R'billion R'billion % R'billion %
Revenue 21,9 19,8 +11 19,8 +11
Normalised EBITDA 6,3 5,5 +15 5,6 +13
NHEPS (cents) 871,9 692,0 +26 695,2 +25
*Restatement of performance for the six months to 31 December 2016 at the average exchange rates for the
six months ended 31 December 2017.
From this point forward in the commentary, all December 2016 revenue numbers are stated in CER and all
percentage changes in revenue between December 2017 and December 2016 are based on December 2016 CER revenue
in order to enhance the comparability of underlying performance.
SEGMENTAL PERFORMANCE
Therapeutic Focused Brands
Therapeutic Focused Brands comprising the Anaesthetics, Thrombosis and High Potency & Cytotoxic portfolios,
delivered revenue of R9,9 billion contributing 45% of total Group revenue. The gross profit margin from
Therapeutic Focused Brands expanded due to the benefits from the acquisition of the residual rights to the
AZ Anaesthetics and the realisation of synergies.
Anaesthetics Brands
Revenue of R4,4 billion was achieved, an increase of 59%. The inclusion of the AZ Anaesthetics acquisition
for the full six months compared to four months in the prior period helped elevate the growth rate. Developed
Europe remained the largest contributor (R1,1 billion), followed by China (R0,9 billion) and Japan
(R0,7 billion). The sound performance from this portfolio was constrained by disruptions in supply from the
AZ production network during the period.
Thrombosis Brands
All of the Thrombosis Brands showed excellent growth. The portfolio grew revenue by 17% to R3,3 billion,
increasing 28% in Emerging Markets2 and 10% in Developed Markets3. Performance was enhanced by the addition
of Fraxiparine and Arixtra in China effective 1 January 2017. Compared to the revenue from the portfolio in
the second half of the 2017 financial year, which included the products in China for the full period, the
portfolio grew by 7%.
High Potency & Cytotoxic Brands
Revenue from High Potency & Cytotoxic Brands declined 8% to R2,2 billion. Supply constraints for the Ovestin
brand and product returns in the USA arising from a change in pack size were the primary causes. This offset
good results from the balance of the portfolio in Emerging Markets which grew revenue 8%.
Other Pharmaceuticals
Other Pharmaceuticals comprise Regional Brands and Manufacturing. Revenue from this category increased
by 2% to R10,4 billion while the gross profit remained relatively flat.
Regional Brands
Regional Brands comprise 33% of Group revenue with Sub-Saharan Africa ("SSA") and Australasia making up more
than 80% of this category. Revenue from Regional Brands increased by 4% to R7,2 billion. The absence of
Hydroxyprogesterone Caproate ("HPC") sales in the period resulted in reduced sales in the USA. Excluding HPC
from the results, the underlying revenue growth in the Regional Brands was 10%. SSA was the primary growth
driver, underpinned by the South African business which raised revenue 21%. The Asia Pacific countries and
Brazil also returned good revenue growth.
Manufacturing
Manufacturing revenue was flat at R3,2 billion. Revenue from sales of active pharmaceutical ingredients
improved 6% to R2,3 billion. Revenue from finished-dose-form sales declined 16%, largely as a
consequence of Aspen's acquisition of the Thrombosis Brands in China which the Group previously supplied to
GlaxoSmithKline.
Nutritionals
Revenue from Nutritionals was unchanged from the prior period at R1,6 billion. Sales were stable in each of
Australasia, SSA and Latin America, being the three territories in which the Nutritionals Brands are sold. The
transition of the S-26 and SMA brands to Aspen's new global infant milk formula brand, Alula, has commenced in
Australasia with strong performance in stage 3 and 4 products since launch. Aspen also recorded its first
sales of Alula in China during the period.
FUNDING
Debt levels remain comfortably within the lenders' covenants. Borrowings, net of cash, increased by
R6,0 billion to R43,1 billion. Operating cash generated of R3,0 billion was offset by R9,4 billion of payments
relating to acquisitions, other capital expenditure and dividends to shareholders. Operating cash flow per
share of 658 cents represented a 78% rate of conversion of operating profit as the settlement of acquisition
related trade creditors lifted the investment in working capital. Net interest paid was covered eight times
by EBITDA.
PROSPECTS
The favourable results for the past period extend the good performance delivered in the second half of the
2017 financial year, clearly demonstrating Aspen's successful transition to a therapeutically focused
multinational pharmaceutical group.
The sales achieved in the first half of the 2018 financial year are expected to be maintained in the
second half in spite of the continued supply constraints which will prevent realisation of full potential.
Over the six months ended 31 December 2017, revenue from Commercial Pharmaceuticals grew 22% in Emerging Markets,
making up 54% of revenue from this segment. Emerging Markets should continue to be the most important contributor
to growth.
Performance in the second half will benefit from the additional rights to the AZ Anaesthetics for the full
six months. Operating expenses should stabilise at present levels while net interest paid is expected to rise
and there is no certainty that the exchange gains of the first half will be repeated.
It is anticipated that operating cash flows will remain strong and a conversion rate of 100% of operating
profits is targeted for the full financial year.
The Group results are inevitably influenced by relative currency movements given that 80% of sales are not
denominated in ZAR. Should the current strengthening of the ZAR against other trading currencies be maintained,
sales from offshore territories will convert into a lower value of ZAR revenue. This potential unfavourable
dilution will be partially offset by a weakening USD which reduces the cost of goods, given that a material
portion of purchases are priced in USD.
The 2018 financial year is Aspen's twentieth as a company listed on the JSE Ltd. The Group has a proud
record of reporting NHEPS growth for each of the preceding nineteen years and this year should be no
different.
By order of the Board
K D Dlamini S B Saad
(Chairman) (Group Chief Executive)
Woodmead
8 March 2018
1 Operating profit before depreciation and amortisation adjusted for specific non-trading items
as defined in the Group’s accounting policy.
2 Emerging Markets as defined by MSCI ACWI Index and Frontier Markets Index
3 Developed Markets as defined by MSCI ACWI Index and Frontier Markets Index.
GROUP STATEMENT OF FINANCIAL POSITION
Unaudited Unaudited Audited
31 December 31 December 30 June
2017 2016 2017
R'billion R'billion R'billion
ASSETS
Non-current assets
Intangible assets 67,3 53,6 60,0
Property, plant and equipment 10,1 9,7 9,7
Goodwill 6,0 5,7 5,9
Deferred tax assets 1,0 1,0 1,0
Contingent environmental
indemnification assets 0,7 0,7 0,7
Other non-current assets 1,3 1,1 0,9
Total non-current assets 86,4 71,8 78,2
Current assets
Inventories 13,6 13,2 13,6
Receivables and other current assets 13,8 13,5 13,6
Cash and cash equivalents 8,5 9,5 10,7
Total operating current assets 35,9 36,2 37,9
Assets classified as held-for-sale 0,2 0,1 0,2
Total current assets 36,1 36,3 38,1
Total assets 122,5 108,1 116,3
SHAREHOLDERS' EQUITY
Reserves 42,4 37,7 41,2
Share capital (including treasury shares) 1,9 1,9 1,9
Total shareholders' equity 44,3 39,6 43,1
LIABILITIES
Non-current liabilities
Borrowings 29,5 35,7 28,9
Other non-current liabilities 3,2 3,3 4,5
Unfavourable and onerous contracts 1,5 1,8 1,6
Deferred tax liabilities 2,3 1,9 2,1
Contingent environmental liabilities 0,7 0,7 0,7
Retirement and other employee benefits 0,6 0,6 0,6
Total non-current liabilities 37,8 44,0 38,4
Current liabilities
Borrowings* 22,0 9,4 18,9
Trade and other payables 9,5 10,0 10,3
Other current liabilities 8,6 4,8 5,3
Unfavourable and onerous contracts 0,3 0,3 0,3
Total current liabilities 40,4 24,5 34,8
Total liabilities 78,2 68,5 73,2
Total equity and liabilities 122,5 108,1 116,3
Number of shares in issue
(net of treasury shares) ('000) 456,1 456,0 456,0
Net asset value per share (cents) 9 714,8 8 675,4 9 453,7
* Includes bank overdrafts.
GROUP STATEMENT OF COMPREHENSIVE INCOME
Unaudited Unaudited
six months six months Audited
ended ended year ended
31 December 31 December 30 June
2017 2016 2017
Notes Change R'billion R'billion R'billion
Revenue 11% 21,9 19,8 41,2
Cost of sales (10,7) (10,3) (21,3)
Gross profit 17% 11,2 9,5 19,9
Selling and distribution expenses (3,8) (3,2) (6,7)
Administrative expenses (1,6) (1,3) (2,8)
Other operating income 0,1 0,2 0,3
Other operating expenses (0,8) (0,6) (2,4)
Operating profit B# 13% 5,1 4,6 8,3
Investment income C# 0,2 0,1 0,3
Financing costs D# (0,9) (1,3) (2,4)
Profit before tax 30% 4,4 3,4 6,2
Tax (0,7) (0,6) (1,1)
Profit for the period/year 30% 3,7 2,8 5,1
OTHER COMPREHENSIVE INCOME, NET OF TAX*
Currency translation losses E# (1,1) (4,8) (3,5)
Net (losses)/gains from cash flow
hedging in respect of business
acquisition (0,1) 0,2 0,2
Total comprehensive income/(loss)^ 2,5 (1,8) 1,8
Weighted average number of
shares in issue ('000) 456,4 456,3 456,4
Diluted weighted average number of
shares in issue ('000) 456,4 456,3 456,4
EARNINGS PER SHARE
Basic earnings per share (cents) 30% 806,0 618,6 1 123,4
Diluted earnings per share (cents) 30% 806,0 618,6 1 123,4
DISTRIBUTION TO SHAREHOLDERS
Dividend per share (cents) 287,0 248,0 248,0
The dividend to shareholders of 287,0 cents relates to the dividend declared on 14 September 2017 and paid
on 9 October 2017 (2016: The dividend declared of 248,0 cents relates to the dividend declared on
14 September 2016 and paid on 10 October 2016).
# See notes on Supplementary Information.
* The annual remeasurement of retirement and other employee benefits will not be reclassified to profit and loss.
All other items in other comprehensive income may be reclassified to profit and loss.
^ Total comprehensive income is disclosed net of income from non-controlling interests which are not material.
GROUP STATEMENT OF HEADLINE EARNINGS
Unaudited Unaudited
six months six months Audited
ended ended year ended
31 December 31 December 30 June
2017 2016 2017
Change R'billion R'billion R'billion
HEADLINE EARNINGS^
Reconciliation of headline earnings
Profit attributable to equity holders
of the parent 30% 3,7 2,8 5,1
Adjusted for:
- Net impairment of property, plant and
equipment (net of tax) - - 0,2
- Impairment of intangible assets (net of tax) 0,2 - 0,4
- Loss on the sale of intangible assets (net of tax) - 0,1 0,1
- Loss on the sale of subsidiary (net of tax) - - 0,1
31% 3,9 2,9 5,9
HEADLINE EARNINGS PER SHARE
Headline earnings per share (cents) 31% 842,5 640,9 1 299,5
Diluted headline earnings per share (cents) 31% 842,5 640,9 1 299,5
NORMALISED HEADLINE EARNINGS
Reconciliation of normalised headline earnings
Headline earnings 31% 3,9 2,9 5,9
Adjusted for:
- Restructuring costs (net of tax) 0,1 - 0,4
- Transaction costs (net of tax) 0,1 0,2 0,3
- Foreign exchange gain on acquisitions (net of tax) (0,2) - (0,1)
- Product litigation costs (net of tax) 0,1 - 0,2
26% 4,0 3,1 6,7
NORMALISED HEADLINE EARNINGS PER SHARE
Normalised headline earnings per share (cents) 26% 871,9 692,0 1 463,2
Normalised diluted headline earnings per share (cents) 26% 871,9 692,0 1 463,2
^ Headline earnings is disclosed net of income from non-controlling interests which are not material.
GROUP STATEMENT OF CHANGES IN EQUITY
Share capital
(including
treasury
shares) Reserves Total*
R'billion R'billion R'billion
BALANCE AT 1 JULY 2016 1,9 40,6 42,5
Total comprehensive loss - (1,8) (1,8)
Profit for the period - 2,8 2,8
Other comprehensive loss - (4,6) (4,6)
Dividends paid - (1,1) (1,1)
BALANCE AT 31 DECEMBER 2016 1,9 37,7 39,6
BALANCE AT 1 JULY 2017 1,9 41,2 43,1
Total comprehensive income - 2,5 2,5
Profit for the period - 3,7 3,7
Other comprehensive loss - (1,2) (1,2)
Dividends paid - (1,3) (1,3)
BALANCE AT 31 DECEMBER 2017 1,9 42,4 44,3
* Total shareholders' equity is disclosed net of income from non-controlling interests which are not
material.
GROUP STATEMENT OF CASH FLOWS
Unaudited Unaudited
six months six months Audited
ended ended year ended
31 December 31 December 30 June
2017 2016 2017
Notes Change R'billion R'billion R'billion
CASH FLOWS FROM OPERATING ACTIVITIES
Cash operating profit 6,1 5,5 10,8
Changes in working capital (1,5) (0,7) (0,9)
Cash generated from operations 4,6 4,8 9,9
Net financing costs paid (0,6) (0,9) (1,9)
Tax paid (1,0) (0,7) (1,5)
Cash generated from operating activities (7%) 3,0 3,2 6,5
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditure - property, plant
and equipment A# (0,8) (0,7) (1,5)
Capital expenditure - intangible assets A# (3,0) (0,6) (1,1)
Additions to intangible assets (8,6) (0,6) (1,1)
Consideration outstanding 5,6 - -
Proceeds received on the sale of
intangible assets - - 0,8
Acquisition of subsidiaries and businesses J# - (6,0) (9,5)
Hedging gains - 0,2 -
Increase in other non-current assets (0,3) (0,6) (0,3)
Payment of deferred consideration relating
to prior year business acquisitions (4,0) (0,2) (0,2)
Proceeds on the sale of assets classified
as held-for-sale - 0,1 0,1
Cash used in investing activities (8,1) (7,8) (11,7)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from borrowings 6,4 6,0 6,2
Dividends paid (1,3) (1,1) (1,2)
Cash generated from financing activities 5,1 4,9 5,0
Movement in cash and cash equivalents before
currency translation movements - 0,3 (0,2)
Currency translation movements (0,1) (0,7) (0,5)
Movement in cash and cash equivalents (0,1) (0,4) (0,7)
Cash and cash equivalents at the beginning
of the period/year 7,2 7,9 7,9
Cash and cash equivalents at the end of the
period/year 7,1 7,5 7,2
Operating cash flow per share (cents) (7%) 657,8 708,7 1 421,4
RECONCILIATION OF CASH AND CASH EQUIVALENTS
Cash and cash equivalents per the statement
of financial position 8,5 9,5 10,7
Less: bank overdrafts (1,4) (2,0) (3,5)
7,1 7,5 7,2
For the purposes of the statement of cash flows, cash and cash equivalents comprise cash-on-hand plus deposits
held on call with banks less bank overdrafts.
# See notes on Supplementary Information.
GROUP SEGMENTAL ANALYSIS
Unaudited six months ended 31 December 2017
Therapeutic
Focused Other Total
Brands Pharmaceuticals Pharmaceuticals Nutritionals Total
R'billion R'billion R'billion R'billion R'billion
Revenue 9,9 10,4 20,3 1,6 21,9
Cost of sales (4,2) (5,6) (9,8) (0,9) (10,7)
Gross profit 5,7 4,8 10,5 0,7 11,2
Selling and distribution
expenses (3,3) (0,5) (3,8)
Contribution profit 7,2 0,2 7,4
Administrative expenses (1,6)
Net other operating income 0,1
Depreciation 0,4
Normalised EBITDA* 6,3
Adjusted for:
Depreciation (0,4)
Amortisation (0,3)
Net impairment of assets (0,2)
Restructuring costs (0,1)
Transaction costs (0,1)
Product litigation costs (0,1)
Operating profit 5,1
Gross profit (%) 56,9 46,2 51,4 45,2 51,0
Selling and distribution
expenses (%) 16,2 30,6 17,2
Contribution profit (%) 35,3 14,7 33,8
Administrative expenses (%) 7,2
Normalised EBITDA (%) 28,8
Unaudited restated six months ended 31 December 2016
Therapeutic
Focused Other Total
Brands Pharmaceuticals Pharmaceuticals Nutritionals Total
R'billion R'billion R'billion R'billion R'billion
Revenue 8,0 10,2 18,2 1,6 19,8
Cost of sales (4,1) (5,3) (9,4) (0,9) (10,3)
Gross profit 3,9 4,9 8,8 0,7 9,5
Selling and distribution
expenses (2,7) (0,5) (3,2)
Contribution profit 6,1 0,2 6,3
Administrative expenses (1,3)
Net other operating income 0,2
Depreciation 0,3
Normalised EBITDA* 5,5
Adjusted for:
Depreciation (0,3)
Amortisation (0,3)
Loss on sale of assets (0,1)
Transaction costs (0,1)
Net impairment of assets (0,1)
Operating profit 4,6
Gross profit (%) 49,2 48,3 48,7 43,3 48,2
Selling and distribution
expenses (%) 15,2 27,9 16,2
Contribution profit (%) 33,5 15,4 32,0
Administrative expenses (%) 6,9
Normalised EBITDA (%) 27,7
* Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific
non-trading items as defined in the Group's accounting policy.
Change
Therapeutic
Focused Other Total
Brands Pharmaceuticals Pharmaceuticals Nutritionals Total
Revenue 24% 2% 12% (1%) 11%
Cost of sales 5% 6% 6% (5%) 5%
Gross profit 44% (2%) 18% 3% 17%
Selling and distribution
expenses 19% 8% 17%
Contribution profit 18% (6%) 17%
Administrative expenses 16%
Net other operating income (37%)
Depreciation 9%
Normalised EBITDA * 15%
* Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific
non-trading items as defined in the Group's accounting policy.
GROUP REVENUE SEGMENTAL ANALYSIS
Unaudited
Unaudited restated
six months six months
ended ended
31 December 31 December
2017 2016
R'billion R'billion Change
Commercial pharmaceuticals by customer geography 17,1 15,0 14%
Sub-Saharan Africa 4,0 3,4 16%
Developed Europe 3,9 3,3 17%
Australasia 2,6 2,5 4%
Latin America 1,5 1,2 24%
Developing Europe & CIS 1,4 1,2 23%
China 1,2 0,7 68%
Japan 1,0 0,8 38%
Other Asia 0,8 0,6 32%
MENA 0,4 0,6 (26%)
USA & Canada 0,3 0,7 (60%)
Manufacturing revenue by geography of manufacture
Manufacturing revenue - finished dose form 0,9 1,1 (17%)
Sub-Saharan Africa 0,4 0,5 (24%)
Developed Europe 0,3 0,3 (15%)
Australasia 0,2 0,3 (9%)
Manufacturing revenue - active pharmaceutical ingredients 2,3 2,1 9%
Developed Europe 2,1 1,9 10%
Sub-Saharan Africa 0,2 0,2 (5%)
Total manufacturing revenue 3,2 3,2 0%
Total pharmaceuticals 20,3 18,2 12%
Nutritionals by customer geography 1,6 1,6 (1%)
Australasia 0,4 0,4 (2%)
Sub-Saharan Africa 0,5 0,5 1%
Latin America 0,7 0,7 (8%)
Total revenue 21,9 19,8 11%
Summary of regions
Sub-Saharan Africa 5,1 4,6 9%
Developed Europe 6,3 5,5 13%
Australasia 3,2 3,2 3%
Latin America 2,2 1,9 12%
Developing Europe & CIS 1,4 1,2 23%
China 1,2 0,7 68%
Japan 1,0 0,8 38%
Other Asia 0,8 0,6 32%
MENA 0,4 0,6 (26%)
USA & Canada 0,3 0,7 (60%)
Total revenue 21,9 19,8 11%
COMMERCIAL PHARMACEUTICALS THERAPEUTIC AREA ANALYSIS
Unaudited six months ended 31 December 2017
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
R'billion R'billion R'billion R'billion R'billion R'billion
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 0,1 - - 0,1 3,9 4,0
Developed Europe 1,1 1,8 0,8 3,7 0,2 3,9
Australasia 0,4 - 0,3 0,7 1,9 2,6
Latin America 0,4 0,1 0,4 0,9 0,6 1,5
Developing Europe & CIS 0,2 1,0 0,2 1,4 - 1,4
China 0,9 0,3 - 1,2 - 1,2
Japan 0,7 - 0,2 0,9 0,1 1,0
Other Asia 0,4 0,1 0,1 0,6 0,2 0,8
MENA 0,1 - 0,1 0,2 0,2 0,4
USA & Canada 0,1 - 0,1 0,2 0,1 0,3
Total Commercial
Pharmaceuticals 4,4 3,3 2,2 9,9 7,2 17,1
Unaudited restated six months ended 31 December 2016
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
R'billion R'billion R'billion R'billion R'billion R'billion
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 0,1 - - 0,1 3,3 3,4
Developed Europe 0,7 1,6 0,8 3,1 0,2 3,3
Australasia 0,3 - 0,3 0,6 1,9 2,5
Latin America 0,2 0,1 0,3 0,6 0,6 1,2
Developing Europe & CIS - 0,9 0,2 1,1 0,1 1,2
China 0,7 - - 0,7 - 0,7
Japan 0,4 - 0,3 0,7 0,1 0,8
Other Asia 0,2 0,1 0,1 0,4 0,2 0,6
MENA 0,1 0,1 0,2 0,4 0,2 0,6
USA & Canada 0,1 - 0,2 0,3 0,4 0,7
Total Commercial
Pharmaceuticals 2,8 2,8 2,4 8,0 7,0 15,0
Variances
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 15% 39% (19%) 1% 17% 16%
Developed Europe 56% 15% (5%) 20% (19%) 17%
Australasia 20% (13%) 2% 11% 2% 4%
Latin America >100% (46%) 28% 45% 1% 24%
Developing Europe & CIS >100% 15% (5%) 24% (5%) 23%
China 34% 100% (79%) 68% - 68%
Japan 59% (28%) (6%) 34% 67% 38%
Other Asia >100% (22%) 18% 46% (1%) 32%
MENA 14% (47%) (53%) (30%) (19%) (26%)
USA & Canada 63% (50%) (64%) (22%) (87%) (60%)
Total Commercial
Pharmaceuticals 57% 20% (9%) 24% 3% 14%
GROUP SUPPLEMENTARY INFORMATION
Unaudited Unaudited
six months six months Audited
ended ended year ended
31 December 31 December 30 June
2017 2016 2017
R'billion R'billion R'billion
A. CAPITAL EXPENDITURE
Incurred 3,8 1,3 2,6
- Property, plant and equipment 0,8 0,7 1,5
- Intangible assets 3,0 0,6 1,1
Contracted 0,8 0,8 0,8
- Property, plant and equipment 0,8 0,8 0,7
- Intangible assets - - 0,1
Authorised but not contracted for 5,7 2,1 6,0
- Property, plant and equipment 5,4 1,7 5,6
- Intangible assets 0,3 0,4 0,4
B. OPERATING PROFIT HAS BEEN ARRIVED AT AFTER CHARGING
Depreciation of property, plant and equipment 0,4 0,3 0,7
Amortisation of intangible assets 0,3 0,3 0,6
Net impairment of tangible and intangible assets 0,2 0,1 0,7
Loss on the sale of tangible and intangible assets - 0,1 0,1
Transaction costs 0,1 0,1 0,3
Restructuring costs 0,1 - 0,4
Product litigation costs 0,1 - 0,2
Loss on sale of subsidiary - - 0,1
C. INVESTMENT INCOME
Interest received 0,2 0,1 0,3
D. FINANCING COSTS
Interest paid (0,9) (0,9) (1,9)
Debt raising fees on acquisitions (0,1) (0,1) (0,1)
Fair value gains/(losses) on financial instruments 0,1 (0,1) (0,2)
Notional interest on financial instruments (0,2) (0,2) (0,3)
Foreign exchange gain on acquisitions 0,2 - 0,1
(0,9) (1,3) (2,4)
E. CURRENCY TRANSLATION LOSSES
Currency translation losses on the translation of the
offshore businesses are as a result of the difference
between the weighted average exchange rate used for trading
results and the opening and closing exchange rates applied
in the statement of financial position. For the six months
the stronger closing Rand translation rate decreased the
Group net asset value. (1,1) (4,8) (3,5)
F. GUARANTEES TO FINANCIAL INSTITUTIONS
Material guarantees given by Group companies for indebtedness
of subsidiaries to financial institutions 58,7 53,2 55,1
G. RESOLVED INCOME TAX MATTER
The Aspen Group was subject to an international tax and transfer pricing audit by the South African Revenue
Service ("SARS") and Aspen Pharmacare Holdings Limited received a revised assessment in relation to its 2011
fiscal year as a consequence of this audit. Aspen, with the assistance of its legal and tax advisers, entered
into discussions with SARS which has resulted in the assessment being reversed by SARS.
H. POTENTIAL DISPUTED MATTER - EUROPEAN COMMISSION
The European Commission (the "Commission") has instituted an investigation of Aspen Pharmacare Holdings Limited
and certain of its indirect wholly owned subsidiaries under Article 102 of the Treaty on the Functioning of the
European Union ("Article 102") in respect of the molecules (i) Chlorambucil; (ii) Melphalan; (iii) Mercaptopurine;
(iv) Thioguanine; and (v) Busulfan, for (a) alleged setting of unfair and excessive pricing in the form of
significant price increases; (b) alleged unfair/abusive negotiating practices; (c) alleged stock allocation
strategies designed to reduce supply; and (d) alleged practices hindering parallel trade, in the European Economic
Area (excluding Italy).
The Commission has confirmed that at this stage it has "no firm conclusions" of whether Aspen Pharmacare Holdings
Limited and/or its indirect wholly owned subsidiaries have undertaken any infringement of Article 102 as it requires
to complete its investigation. The Commission's decision whether to formally open a case is likely only to be made
during the first quarter of 2019 after conclusion of its investigation.
The outcome of the Commission matter is unknown at this stage and therefore no liability has been raised in the statement
of financial position.
I. POTENTIAL DISPUTED MATTER - UK COMPETITION AND MARKETS AUTHORITY
The UK Competition and Markets Authority ("CMA") in October 2017 opened an investigation against Aspen into alleged
anti-competitive conduct in relation to the supply of fludrocortisone acetate 0.1 mg tablets and dexamethasone 2 mg
tablets in the UK. In 2016 the two products had a combined revenue of GBP11.1 million in the UK.
The investigation is at an early stage and the CMA has confirmed that, at this time, it has not reached any conclusion
on whether competition law has been infringed. A high level of cooperation and diligence is being afforded to the
investigation team by Aspen and our advisers.
The outcome of the CMA matter is unknown at this stage and therefore no liability has been raised in the statement of
financial position.
J. ACQUISITION OF SUBSIDIARIES AND BUSINESSES
June 2017
Set out below is the final accounting for the following business combinations:
AstraZeneca anaesthetics portfolio
With effect from 1 September 2016, Aspen Global Incorporated ("AGI") acquired the exclusive rights to commercialise the
anaesthetics portfolio of AstraZeneca globally (excluding the USA). As consideration for the commercialisation rights,
AGI paid USD410 million with a further payment of USD110 million due on 1 July 2017. Additionally, AGI will make
sales-related payments of up to USD250 million based on sales in the 24 months following completion.
Post-acquisition revenue included in the statement of comprehensive income was R6,5 billion. The estimation of
post-acquisition operating profits is impracticable and not reasonably determinable due to the immediate integration
of the business into the existing operations of the Group.
Fraxiparine and Arixtra in China, Pakistan and India
As part of its acquisition of the thrombosis products Fraxiparine and Arixtra from GlaxoSmithKline ("GSK") in 2014, AGI
also acquired an option to purchase the same products in certain countries to which GSK retained the rights, most notably
China. AGI has exercised its option and, with effect from 1 January 2017, acquired Fraxiparine and Arixtra in these
countries for a consideration of GBP45 million.
Post-acquisition revenue included in the statement of comprehensive income was R0,3 billion. The estimation of
post-acquisition operating profits is impracticable and not reasonably determinable due to the immediate integration of
the business into the existing operations of the Group.
GSK anaesthetics portfolio
With effect from 1 March 2017 AGI acquired a portfolio of anaesthetics globally (excluding the USA) from GSK. As consideration
for the commercialisation rights, AGI paid GBP180 million with further potential milestone payments of up to GBP100 million,
based on the results of the acquired portfolio in the 36 months following completion.
Post-acquisition revenue included in the statement of comprehensive income was R0,5 billion. The estimation of post-acquisition
operating profits is impracticable and not reasonably determinable due to the immediate integration of the business into the
existing operations of the Group.
Fraxiparine
and Arixtra
AstraZeneca in China, GSK
anaesthetics Pakistan anaesthetics
portfolio and India portfolio Total
R'billion R'billion R'billion R'billion
Fair value of assets and liabilities acquired
Intangible assets 11,1 0,7 4,4 16,2
Deferred tax liabilities (0,3) - (0,1) (0,4)
Fair value of net assets acquired 10,8 0,7 4,3 15,8
Goodwill acquired 0,3 - 0,1 0,4
Net gains from cash flow hedging in respect of
business acquisition - - (0,2) (0,2)
Deferred and contingent consideration (5,0) - (1,5) (6,5)
Cash outflow on acquisition 6,1 0,7 2,7 9,5
K. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA
The Group has presented selected line items from the consolidated statement of comprehensive income and certain trading
profit metrics on a constant exchange rate basis in the tables below.
The pro forma constant exchange rate information is presented to demonstrate the impact of fluctuations in currency exchange
rates on the Group's reported results. The constant exchange rate report is the responsibility of the Group's Board of
Directors and is presented for illustrative purposes only. Due to the nature of this information, it may not fairly present
the Group's financial position, changes in equity and results of operations or cash flows. The pro forma information has been
compiled in terms of the JSE Listings Requirements and the Revised Guide on Pro Forma Information by SAICA and the accounting
policies of the Group as at 31 December 2017. This information has not been reviewed or audited by the Group's auditors.
The Group's financial performance is impacted by numerous currencies which underlie the reported trading results, where even
within geographic segments, the Group trades in multiple currencies ("source currencies"). The constant exchange rate restatement
has been calculated by adjusting the prior year's reported results at the current year's reported average exchange rates. Restating
the prior year's numbers provides illustrative comparability with the current year's reported performance by adjusting the estimated
effect of source currency movements.
The listing of average exchange rates against the Rand for the currencies contributing materially to the impact of exchange rate
movements are set out below:
2017 2016
average average
rates rates
EUR - Euro 15,774 15,251
USD - US Dollar 13,410 13,941
AUD - Australia Dollar 10,447 10,458
JPY - Japanese Yen 0,120 0,131
CNY - Chinese Yuan Renminbi 2,019 2,060
MXN - Mexican Peso 0,723 0,715
BRL - Brazilian Real 4,148 4,270
GBP - British Pound 17,672 17,751
RUB - Russian Ruble 0,229 0,218
PLN - Polish Zloty 3,714 3,501
CAD - Canadian Dollar 10,627 10,507
Revenue, other income, cost of sales and expenses
For purposes of the constant exchange rate report the prior year's source currency revenue, cost of sales and expenses have
been restated from the prior year's relevant average exchange rate to the current year's relevant reported average exchange
rate.
Interest paid net of investment income
Net interest paid is directly linked to the source currency of the borrowing on which it is levied and is restated from the
prior year's relevant reported average exchange rate to the current year's relevant reported average exchange rate.
Tax
The tax charge for purposes of the constant currency report has been recomputed by applying the actual effective tax rate to
the restated profit before tax for the relevant legal entity.
Reported Reported Illustrative
31 December 31 December constant
2017 2016 exchange
(31 December (31 December rates
2017 2016 (31 December
at 2017 at 2016 Change at 2016 at Change in
average average reported 2017 average constant
rates) rates) exchange rates) exchange
Key constant exchange rate indicators R'billion R'billion rates R'billion rates
Revenue 21,9 19,8 11% 19,8 11%
Gross profit 11,2 9,5 17% 9,6 16%
Normalised EBITDA 6,3 5,5 15% 5,6 13%
Operating profit 5,1 4,6 13% 4,6 10%
Normalised headline earnings 4,0 3,1 26% 3,2 25%
Earnings per share (cents) 806,0 618,6 30% 623,4 29%
Headline earnings per share (cents) 842,5 640,9 31% 644,1 31%
Normalised headline earnings
per share (cents) 871,9 692,0 26% 695,2 25%
GROUP REVENUE SEGMENTAL ANALYSIS
Reported Reported Illustrative
31 December 31 December constant
2017 2016 exchange rate
(31 December (31 December 31 December
2017 2016 2016
at 2017 at 2016 (31 December Change at
average average 2016 at 2017 constant
rates) rates) average rates) exchange
R'billion R'billion R'billion rates
Commercial pharmaceuticals by customer geography 17,1 15,0 14,9 15%
Sub-Saharan Africa 4,0 3,4 3,4 17%
Developed Europe 3,9 3,3 3,4 14%
Australasia 2,6 2,5 2,5 5%
Latin America 1,5 1,2 1,2 25%
Developing Europe & CIS 1,4 1,2 1,2 19%
China 1,2 0,7 0,7 74%
Japan 1,0 0,8 0,7 50%
Other Asia 0,8 0,6 0,6 37%
MENA 0,4 0,6 0,5 (17%)
USA & Canada 0,3 0,7 0,7 (58%)
Manufacturing revenue by geography of manufacture
Manufacturing revenue - finished dose form 0,9 1,1 1,1 (16%)
Sub-Saharan Africa 0,4 0,5 0,5 (23%)
Developed Europe 0,3 0,3 0,4 (20%)
Australasia 0,2 0,3 0,2 4%
Manufacturing revenue - active pharmaceutical
ingredients 2,3 2,1 2,2 6%
Developed Europe 2,1 1,9 2,0 7%
Sub-Saharan Africa 0,2 0,2 0,2 (5%)
Total manufacturing revenue 3,2 3,2 3,3 (1%)
Total pharmaceuticals 20,3 18,2 18,2 11%
Nutritionals by customer geography 1,6 1,6 1,6 (1%)
Australasia 0,4 0,4 0,4 (2%)
Sub-Saharan Africa 0,5 0,5 0,5 1%
Latin America 0,7 0,7 0,7 (7%)
Total revenue 21,9 19,8 19,8 11%
Summary of regions
Sub-Saharan Africa 5,1 4,6 4,6 10%
Developed Europe 6,3 5,5 5,8 9%
Australasia 3,2 3,2 3,1 4%
Latin America 2,2 1,9 1,9 13%
Developing Europe & CIS 1,4 1,2 1,2 19%
China 1,2 0,7 0,7 74%
Japan 1,0 0,8 0,7 50%
Rest of Asia 0,8 0,6 0,6 37%
MENA 0,4 0,6 0,5 (17%)
USA & Canada 0,3 0,7 0,7 (58%)
Total revenue 21,9 19,8 19,8 11%
COMMERCIAL PHARMACEUTICALS THERAPEUTIC AREA ANALYSIS
Reported 31 December 2017 (31 December 2017 at 2017 average rates)
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
R'billion R'billion R'billion R'billion R'billion R'billion
By customer geography
Commercial Pharmaceuticals
Sub-Saharan Africa 0,1 - - 0,1 3,9 4,0
Developed Europe 1,1 1,8 0,8 3,7 0,2 3,9
Australasia 0,4 - 0,3 0,7 1,9 2,6
Latin America 0,4 0,1 0,4 0,9 0,6 1,5
Developing Europe & CIS 0,2 1,0 0,2 1,4 - 1,4
China 0,9 0,3 - 1,2 - 1,2
Japan 0,7 - 0,2 0,9 0,1 1,0
Other Asia 0,4 0,1 0,1 0,6 0,2 0,8
MENA 0,1 - 0,1 0,2 0,2 0,4
USA & Canada 0,1 - 0,1 0,2 0,1 0,3
Total Commercial Pharmaceuticals 4,4 3,3 2,2 9,9 7,2 17,1
Reported 31 December 2016 (31 December 2016 at 2016 average rates)
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
R'billion R'billion R'billion R'billion R'billion R'billion
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 0,1 - - 0,1 3,3 3,4
Developed Europe 0,7 1,6 0,8 3,1 0,2 3,3
Australasia 0,3 - 0,3 0,6 1,9 2,5
Latin America 0,2 0,1 0,3 0,6 0,6 1,2
Developing Europe & CIS - 0,9 0,2 1,1 0,1 1,2
China 0,7 - - 0,7 - 0,7
Japan 0,4 - 0,3 0,7 0,1 0,8
Other Asia 0,2 0,1 0,1 0,4 0,2 0,6
MENA 0,1 0,1 0,2 0,4 0,2 0,6
USA & Canada 0,1 - 0,2 0,3 0,4 0,7
Total Commercial Pharmaceuticals 2,8 2,8 2,4 8,0 7,0 15,0
Illustrative constant exchange rate 31 December 2016
(31 December 2016 at 2017 average rates)
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
R'billion R'billion R'billion R'billion R'billion R'billion
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 0,1 - - 0,1 3,3 3,4
Developed Europe 0,7 1,6 0,8 3,1 0,3 3,4
Australasia 0,3 - 0,3 0,6 1,9 2,5
Latin America 0,2 0,1 0,4 0,7 0,5 1,2
Developing Europe & CIS - 0,9 0,2 1,1 0,1 1,2
Japan 0,4 - 0,2 0,6 0,1 0,7
China 0,7 - - 0,7 - 0,7
Other Asia 0,2 0,1 0,1 0,4 0,2 0,6
MENA 0,1 0,1 0,1 0,3 0,2 0,5
USA & Canada 0,1 - 0,2 0,3 0,4 0,7
Total Commercial Pharmaceuticals 2,8 2,8 2,3 7,9 7,0 14,9
% change constant exchange rates
High Potency Therapeutic
Anaesthetics Thrombosis & Cytotoxic Focused Regional
Brands Brands Brands Brands Brands Total
BY CUSTOMER GEOGRAPHY
Commercial Pharmaceuticals
Sub-Saharan Africa 15% 39% (19%) 1% 17% 17%
Developed Europe 52% 11% (7%) 16% (20%) 14%
Australasia 20% (13%) 3% 12% 2% 5%
Latin America >100% (7%) 15% 44% 4% 25%
Developing Europe & CIS >100% 11% (7%) 19% 0% 19%
China >100% >100% (96%) 85% (100%) 74%
Japan 9% >100% >100% 37% >100% 50%
Other Asia >100% (18%) 22% 52% 4% 37%
MENA 22% (38%) (42%) (20%) (14%) (17%)
USA & Canada 61% (50%) (63%) (21%) (87%) (58%)
Total Commercial Pharmaceuticals 59% 17% (8%) 24% 4% 15%
BASIS OF ACCOUNTING
The unaudited interim financial results for the six months ended 31 December 2017 have been prepared in
accordance with International Financial Reporting Standards, IFRIC interpretations, the Listings Requirements
of the JSE Limited, South African Companies Act, 2008 and the presentation and disclosure requirements of
IAS 34: Interim Reporting.
The accounting policies applied in the preparation of the unaudited interim financial results are in terms
of International Financial Reporting Standards and are consistent with those applied in the annual financial
statements for the year ended 30 June 2017 except for changes to the segmental analysis which are explained
in detail below.
The unaudited interim financial results have been rounded and disclosed in Rand billions to assist financial
analysis. All percentage change variances have been calculated using unrounded numbers to record accurate
variance trends.
These unaudited interim financial results were prepared under the supervision of the Deputy Group Chief
Executive, M G Attridge CA(SA) and approved by the Board of Directors.
Restatement of Group reportable segments
The Group revised its reportable segments for the financial year ended 30 June 2017 to reflect the current
operating model and to achieve alignment with the change in the way in which the business is managed and
reported on by the Chief Operating Decision Maker (“CODM”). The regional reporting segments of International,
South Africa, Asia Pacific and Sub-Saharan Africa have been replaced by the Pharmaceutical and Nutritional
business reporting segments. The Pharmaceutical business reporting segment has been further split into
Therapeutic Focused Brands and Other Pharmaceuticals.
Therapeutic Focused Brands consist of those brands in the portfolios comprising Aspen's three major
pharmaceutical therapeutic areas, being Anaesthetics, Thrombosis and High Potency & Cytotoxics. Other
Pharmaceuticals consists of the revenue from the Regional Pharmaceutical Brands as well as Manufacturing
revenue relating to both active pharmaceutical ingredients and finished dose form products.
The entity-wide revenue disclosure has been revised to reflect the three therapeutic areas which constitute
the Therapeutic Focused Brands with the balance of the Commercial pharmaceutical brands being recorded as
Regional Brands. The regions have been further refined to split Europe CIS into Developed Europe and
Developing Europe & CIS segments. The Asia Pacific region has been split into the following segments:
- Australasia;
- China;
- Japan; and
- Other Asia
The GSK Aspen Healthcare for Africa Collaboration which was a material component of the Sub-Saharan Africa
region was terminated effective from 31 December 2016 and as a consequence the Sub-Saharan Africa region is
no longer a material region. On this basis the South African and Sub-Saharan African regions were consolidated
into a broader all encompassing Sub-Saharan Africa region.
DIRECTORS
K D Dlamini (Chairman)*, R C Andersen*, M G Attridge, J F Buchanan*, C N Mortimer*, B Ngonyama*,
D S Redfern*, S B Saad, S V Zilwa*
*Non-executive director
COMPANY SECRETARY
R Verster
REGISTERED OFFICE
Building Number 8, Healthcare Park, Woodlands Drive, Woodmead
PO Box 1587, Gallo Manor, 2052
Telephone +27 11 239 6100
Telefax +27 11 239 6144
SPONSOR
Investec Bank Limited
TRANSFER SECRETARY
Terbium Financial Services (Pty) Ltd
Beacon House
31 Beacon Road, Florida North, 1709
PO Box 61272, Marshalltown, 2107
www.aspenpharma.com
Disclaimer
We may make statements that are not historical facts and relate to analyses and other information based on
forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements
as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "prospects", "believe",
"anticipate", "expect", "intend", "seek", "will", "plan", "indicate", "could", "may", "endeavour" and "project"
and similar expressions are intended to identify such forward looking statements, but are not the exclusive
means of identifying such statements. By their very nature, forward looking statements involve inherent risks
and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and
other forward looking statements will not be achieved. If one or more of these risks materialise, or should
underlying assumptions prove incorrect, actual results may be very different from those anticipated. The
factors that could cause our actual results to differ materially from the plans, objectives, expectations,
estimates and intentions expressed in such forward looking statements are discussed in each year's annual
report. Forward looking statements apply only as of the date on which they are made, and we do not undertake
other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any
of them, whether as a result of new information, future events or otherwise. Any profit forecasts published
in this report are unaudited.
Date: 08/03/2018 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
